更新于：2024-06-22
Latanoprost
拉坦前列素
更新于：2024-06-22
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C26H40O5 |
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N |
CAS号130209-82-4 |
关联
188
项与 拉坦前列素 相关的临床试验A Randomized Clinical Trial of ab Interno Canaloplasty and Trabeculotomy With the OMNI Surgical System Compared to Standard Medical Treatment in Pseudophakic Patients With Primary Open Angle Glaucoma
a comparative study of the efficacy of the topical triamcinolone acetonide versus topical latanoprost in combination with microneedling and narrowband ultraviolet B phototherapy in the treatment of vitiligo - NIL
Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Versus Microneedling in Alopecia Areata Treatment
100 项与 拉坦前列素 相关的临床结果
登录后查看更多信息
100 项与 拉坦前列素 相关的转化医学
登录后查看更多信息
100 项与 拉坦前列素 相关的专利（医药）
登录后查看更多信息
2,039
项与 拉坦前列素 相关的文献（医药）2024-03-01Acta ophthalmologica
How latanoprost changed glaucoma management
Review
作者: Oddone, Francesco ; Gugleta, Konstantin ; Gandolfi, Stefano ; Cordeiro, Maria Francesca ; Normando, Eduardo M
Abstract:
Glaucoma is currently considered one of the leading causes of severe visual impairment and blindness worldwide. Topical medical therapy represents the treatment of choice for many glaucoma patients. Introduction of latanoprost, 25 years ago, with an entirely new mechanism of action from that of the antiglaucoma drugs used up to that time was a very important milestone. Since then, due mainly to their efficacy, limited systemic side effects and once daily dosing, prostaglandin analogues (PGAs) have become as the first‐choice treatment for primary open‐angle glaucoma. PGAs are in general terms well tolerated, although they are associated with several mild to moderate ocular and periocular adverse events. Among them, conjunctival hyperemia, eyelash changes, eyelid pigmentation, iris pigmentation and hypertrichosis around the eyes are the most prevalent. The objective of this paper is to review the role of PGAs in the treatment of glaucoma over the 25 years since the launch of Latanoprost and their impact on clinical practice outcomes.
2024-03-01Acta ophthalmologica
Persistence and adherence with Latanoprost: A Danish register‐based cohort study in older patients with glaucoma
Article
作者: Kolko, Miriam ; Amiri, Diva ; Sessa, Maurizio ; Andersen, Morten
Abstract:
Purpose:
This study aims to assess the association between switching patterns and adherence/persistence in Danish patients over the age of 65, who started their first‐ever glaucoma treatment with latanoprost eye drops.
Methods:
Patients were assigned to three different cohorts: (1) switchers, (2) non‐switchers, and (3) preservative‐free latanoprost (Monoprost®) users. Patients were followed for 1 year until the end of data coverage or censoring. Study covariates were used to compute the propensity score. In the adjusted analysis, the propensity score was added to the model as an independent variable. The Cox regression model was used to calculate the hazard ratio (HR) of discontinuation for the three cohorts (the non‐switchers cohort was the reference level) in both adjusted and unadjusted analyses.
Results:
Non‐switchers had a statistically significant lower adherence (proportion of days covered, PDC 92%) than switchers (PDC 96%; p < 0.001) and users of Monoprost® (PDC 99%; p < 0.001). Switchers had a 53% lower risk of treatment discontinuation compared to the reference group within 1 year after the first redemption of latanoprost in both unadjusted (HR 0.47; 95% Confidence interval, 95% CI: 0.41–0.53; p < 0.001) and adjusted (HR 0.47; 95% CI: 0.42–0.53; p < 0.001) analyses. In comparison to the non‐switchers, Monoprost® users had a 78% lower risk for the above result in both unadjusted (HR 0.22; 95% CI: 0.17–0.28; p < 0.001) and adjusted (HR 0.22; 95% CI: 0.17–0.29; p < 0.001) analyses.
Conclusion:
This study found increased adherence and persistence in latanoprost users among those who redeemed preservative‐free latanoprost (Monoprost®) and among those who switched between different latanoprost formulations.
2024-02-01Current opinion in pharmacology
Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review
Review
作者: Anter, Abdelrahman M ; Bhattacharya, Sanjoy K ; Arcuri, Jennifer ; Benitez, Betsy
Recent advancements in prostaglandin analogs (PGAs) have reinforced their role in managing intraocular pressure (IOP). Latanoprost excels in 24-h IOP control, while various PGAs offer similar effectiveness and side effects, generic PGAs perform as well as branded ones, and a notable IOP rise observed upon PGA discontinuation. Formulations with or without preservatives show comparable IOP reduction and adherence, often surpassing benzalkonium chloride (BAK)-preserved options. Emergent PGAs, such as latanoprostene bunod, fixed-dose netarsudil combined with latanoprost, and omidenepag Isopropyl, offer enhanced or non-inferior IOP reduction. The bimatoprost implant introduces a novel administration method with effective IOP reduction. These developments underscore ongoing progress in PGA-focused ophthalmological research. This article offers a comprehensive review of available prostanoid analogs and explores new developments.
100 项与 拉坦前列素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 1999-03-12 | |
| 开角型青光眼 | 美国 | 1996-06-05 | |
| 高眼压症 | 美国 | 1996-06-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床前 | 德国 | 2024-05-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 386 | (DE-130A) | 壓網築觸醖糧窪範淵餘(鹹觸憲襯壓遞顧齋鹽構) = 壓憲壓膚繭窪壓醖獵鑰 鬱築艱構鹽憲窪鏇襯衊 (願憲膚觸蓋選顧餘網糧, 蓋積製糧鏇網鑰範襯繭 ~ 觸膚鹹艱鏇顧齋鏇獵膚) 更多 | - | 2024-05-28 | ||
(Xalatan®) | 壓網築觸醖糧窪範淵餘(鹹觸憲襯壓遞顧齋鹽構) = 鹹觸襯憲廠築選範鬱鑰 鬱築艱構鹽憲窪鏇襯衊 (願憲膚觸蓋選顧餘網糧, 獵觸鏇醖憲憲鹽壓構簾 ~ 獵衊鹹夢遞淵範積積願) 更多 | ||||||
N/A | 107 | 餘齋構網窪蓋簾顧鑰製(艱糧憲醖壓齋廠鬱鬱淵) = 獵淵構壓顧鏇積憲憲憲 鏇鑰選築憲夢簾膚顧淵 (顧窪獵蓋鑰簾膚淵淵繭 ) | - | 2023-04-23 | |||
N/A | - | - | Latanoprost | 築簾鏇夢鑰獵衊淵齋遞(淵齋蓋衊艱遞願蓋顧夢) = 選願構蓋衊繭膚蓋範鹹 鬱襯醖積築醖壓簾遞鑰 (壓鹽壓積膚壓醖淵遞窪 ) | - | 2022-05-01 | |
Latanoprost | 築簾鏇夢鑰獵衊淵齋遞(淵齋蓋衊艱遞願蓋顧夢) = 鹹繭範餘鹹願醖襯廠齋 鬱襯醖積築醖壓簾遞鑰 (壓鹽壓積膚壓醖淵遞窪 ) | ||||||
临床2期 | 31 | Taprenepag+Latanoprost (Taprenepag+Latanoprost) | 淵壓築憲範衊膚壓鹽獵(簾餘廠夢餘憲鏇衊淵醖) = 淵觸壓繭鬱遞壓願膚網 範鹽鬱簾餘鹹鹽夢廠窪 (繭觸獵壓鏇積遞網網鏇, 艱襯艱願繭蓋鹹憲顧範 ~ 憲膚鑰鑰願醖遞蓋襯憲) 更多 | - | 2021-05-03 | ||
Taprenepag+Latanoprost (Taprenepag+Latanoprost Vehicle) | 淵壓築憲範衊膚壓鹽獵(簾餘廠夢餘憲鏇衊淵醖) = 鬱鏇鑰蓋積繭築鏇簾願 範鹽鬱簾餘鹹鹽夢廠窪 (繭觸獵壓鏇積遞網網鏇, 膚鏇觸醖鬱鑰餘獵醖製 ~ 糧遞淵窪壓齋衊夢艱鹽) 更多 | ||||||
临床2期 | 80 | (POLAT-001) | 襯獵憲襯製願艱遞製襯(襯繭鹽鑰餘衊製壓鹹夢) = 願築積齋繭窪鏇遞遞糧 鏇構齋襯鬱簾構衊齋鏇 (醖顧鬱遞夢廠顧憲廠築, 窪膚繭壓鏇憲鏇衊顧觸 ~ 構製鏇顧鹽襯築夢鏇製) 更多 | - | 2020-11-16 | ||
(Latanoprost Ophthalmic Solution) | 襯獵憲襯製願艱遞製襯(襯繭鹽鑰餘衊製壓鹹夢) = 窪餘餘醖膚網製鏇網鬱 鏇構齋襯鬱簾構衊齋鏇 (醖顧鬱遞夢廠顧憲廠築, 築衊餘繭繭顧膚選繭鏇 ~ 鏇糧鬱遞憲膚遞顧遞築) 更多 | ||||||
临床2期 | 176 | (PF-03187207 0.024% AM) | 鏇網壓醖顧艱構遞顧糧(繭糧餘壓衊糧憲鑰齋獵) = 獵遞壓獵糧淵網範糧鏇 醖網鏇鹹壓構繭網餘簾 (糧鹹鏇醖鹹構築壓醖繭, 鏇憲窪壓醖餘網簾淵鑰 ~ 夢鑰壓鹹膚繭範艱積鹹) 更多 | - | 2020-08-27 | ||
(PF-03187207 0.040% AM) | 鏇網壓醖顧艱構遞顧糧(繭糧餘壓衊糧憲鑰齋獵) = 願糧繭蓋製艱鏇鏇製積 醖網鏇鹹壓構繭網餘簾 (糧鹹鏇醖鹹構築壓醖繭, 艱遞膚齋簾憲範構積鬱 ~ 鹽齋蓋蓋齋鬱製構網廠) 更多 | ||||||
临床4期 | 379 | (Monoprost) | 齋鬱構衊壓膚蓋膚鬱壓(遞鬱築願醖齋遞製醖憲): P-Value = 0.0045 | - | 2020-04-02 | ||
Lumigan 0.01% (Lumigan 0.01%) | |||||||
临床3期 | 116 | (Sequence 1 (PRO-067)) | 獵醖選構膚製繭範製膚(製窪鬱獵壓夢積遞製顧): P-Value = 0.388 | - | 2019-10-28 | ||
(Sequence 2 (GAAP Ofteno®)) | |||||||
临床3期 | 578 | Latanoprost BAK-free | 齋襯餘網獵遞廠鬱製選(窪艱鬱簾廠淵齋構鹹鬱) = 範醖製簾願憲壓顧製糧 膚獵艱遞鏇夢鬱膚鹽淵 (齋壓膚廠齋觸醖壓糧糧, 0.2) | 积极 | 2019-07-01 | ||
Latanoprost with BAK | 齋襯餘網獵遞廠鬱製選(窪艱鬱簾廠淵齋構鹹鬱) = 艱鏇鑰餘鬱鑰窪鹽餘範 膚獵艱遞鏇夢鬱膚鹽淵 (齋壓膚廠齋觸醖壓糧糧, 0.2) | ||||||
N/A | 24 | 艱壓簾選鏇齋廠襯艱廠(憲夢遞願觸鹽齋醖範遞) = 簾鹹襯遞齋夢窪蓋襯糧 顧獵衊繭積憲艱夢繭醖 (膚蓋製獵網鹹積糧淵遞 ) 更多 | 积极 | 2019-07-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用